Research dossier
CJC-1295 without DAC — GHRH analogue dossier
A GHRH analogue stabilised by four substitutions targeting its cleavage points.
Translated from the French original, which remains the reference version: lire en français →
Molecular identity
| Parameter | Value |
|---|---|
| CAS number | 863288-34-0 |
| Molar mass | 3367.97 g/mol |
| Molecular formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Sequence / nature | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH₂ |
| Purity | ≥99% |
| Appearance | White lyophilised powder |
The values above correspond to the catalogue lot and are reproduced as they stand from the product page. Any discrepancy between this dossier and the product page should be reported before use.
Research context
This compound illustrates an explicit design strategy: identify the enzymatic cleavage points of a native peptide and modify them one by one. The result is a case study in structure-stability relationships, independent of the hormonal axis concerned.
Mechanism studied
CJC-1295 without DAC — also designated modified GRF(1-29) in the literature — is an analogue of the first 29 residues of GHRH (growth hormone-releasing hormone), a fragment that retains most of the affinity of the native 44-amino-acid peptide.
Four substitutions distinguish this analogue from the native sequence. They target identified points of enzymatic vulnerability, in particular the dipeptidyl peptidase-4 (DPP-4) cleavage site at position 2, which is the principal degradation route of native GHRH. The position 2 substitution is the one whose stabilising effect is best documented.
The “without DAC” designation is essential: the DAC (drug affinity complex) variant carries a maleimide group allowing covalent binding to albumin, which lengthens the half-life considerably. The two forms have very different kinetic profiles and are not interchangeable in a protocol.
The GHRHR receptor is Gs-coupled; activation is measured in culture by assaying intracellular cAMP.
In-vitro literature
The published assays rely on pituitary cell lines and on cells expressing recombinant GHRHR, with cAMP measurement. Stability comparisons in the presence of recombinant DPP-4 are a methodological standard.
Bibliographic entry points
- PubMed — peer-reviewed literature
- PubChem — chemical profile and assay data
- NCBI — methodology and receptor references
These links are an entry point into the literature, not an edited selection. None of the sources cited relates to a human use of this material, and consulting them directly is recommended for any protocol design.
Distinguishing this compound from its analogues
Also designated modified GRF(1-29) or mod-GRF. These names cover the form without DAC; the presence of the maleimide group distinguishes the other variant.
The CAS number shown on the product page is the identifier to rely on. Trade names, development codes and customary abbreviations vary from one source to another and are not a reliable identification.
Methodological limits
Confusion between the forms with and without DAC is the most frequent error in the secondary literature. The half-lives differ by an order of magnitude, and a protocol designed for one is unsuited to the other. Always check which is used in any publication cited.
These limits are not formalities: they determine what a protocol using this material can and cannot establish. Making them explicit in the experimental plan avoids attributing to the compound an observation that belongs to the measurement system.
Analytical parameters
A 29-residue peptide. Expected impurities include deletion sequences; mass confirmation by spectrometry is decisive for verifying that the substitutions are present.
| Parameter | Value |
|---|---|
| Storage | Store at −20 °C, protected from light |
| Solubility | Soluble in bacteriostatic water (BAC) |
| Stability | Stable for 24 months at −20 °C; 30 days after reconstitution at 2–8 °C |
| Control methods | RP-HPLC · MS · NMR |
Reconstitution is a matter for the experimental protocol. The volume of solvent determines the final concentration and is not prescribed here: it depends on the design of the experiment and the conditions of the assay.
Resulting concentrations
The table below is arithmetic: it gives the concentration obtained for a given solvent volume, with no recommendation of use.
| Format | 1 ml | 2 ml | 3 ml |
|---|---|---|---|
| 10mg | 10.00 mg/ml | 5.00 mg/ml | 3.33 mg/ml |
These values assume complete dissolution and a peptide content consistent with the lot report. Where the actual quantitative content differs from the nominal mass — a common discrepancy, caused by counter-ions and residual water — the effective concentration is lower than the theoretical value. That is precisely why quantitative content per vial forms part of the verification protocol.
Protocol design
Three points govern the validity of an assay using this material, whatever the question being asked.
The effective concentration is not the nominal concentration. It depends on the actual peptide content of the lot, on complete dissolution and on adsorption to the walls of the container. A concentration check after reconstitution is preferable to assuming a perfect yield.
The actual exposure time may be shorter than the nominal duration where the compound is degraded by the medium. Verify stability under the exact conditions of the assay — medium, serum, temperature, duration — before interpreting an absence of effect.
The control arm must correspond to the vehicle actually used, at the same final concentration. This requirement is unremarkable and remains the most frequent cause of irreproducible results.
Lot verification
The following formats are covered by a Janoshik Analytical report, readable from the product page:
- 10mg — lot report available
| Format | Lot report | Availability |
|---|---|---|
| 10mg | Covered | In stock |
The verification programme covers exclusively the identity and purity of the material, by reversed-phase chromatography and mass spectrometry. It covers neither sterility, nor endotoxins, nor any microbiological characteristic.
Frequently asked questions
How does this product arrive?
As a lyophilised powder in a sealed vial, shipped in insulated, plain packaging. Return the vial to the storage temperature given in the specifications on receipt.
Which solvent should be used for reconstitution?
Bacteriostatic water is the usual reconstitution solvent for lyophilised peptides in a laboratory setting. The volume is a matter for the experimental protocol and the concentration sought; we provide no dosage recommendation.
How long does the material remain stable?
The stability window appears in the specifications table on this page, before and after reconstitution. Those values correspond to the storage conditions stated; any temperature variation shortens them.
Does the analysis report correspond exactly to my vial?
The report linked on this page corresponds to the format selected. Each report is issued by Janoshik Analytical from an anonymously submitted sample, and covers the identity and purity of the peptide.
Can this product be used on humans or animals?
No. It is an analytical grade reference material intended exclusively for in-vitro laboratory research. Any administration to humans or animals is excluded, and no therapeutic, diagnostic or medical claim is made.
See also: CJC-1295, Ipamorelin, GHRP-6: GHRH and GHRP compared
Dossiers in the same category
- GHRP-6 — CAS 87616-84-0
- IGF-1 LR3 — CAS 946870-92-4
- Ipamorelin — CAS 170851-70-4